Advanced Search

Home > Journals > Acta Vulnologica > Past Issues > Acta Vulnologica 2006 March;4(1) > Acta Vulnologica 2006 March;4(1):55-60

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEACTA VULNOLOGICA

A Journal on Physiopathology and Therapy of Chronic Cutaneous Ulcers

Official Journal of the Italian Association for Cutaneous Ulcers
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index

Frequency: Quarterly

ISSN 1721-2596

Online ISSN 1827-1774

 

Acta Vulnologica 2006 March;4(1):55-60

    CLINICAL CASES

TISSUEtech Autograft Systyem™: autologous tissue engineering in the treatment of chronic skin lesions

Soranzo B. 1, Senigaglia D. 1, Brambilla R. 2, Scalise A. 3, Abatangelo G. 4

1 Fidia Advanced Biopolymers - Abano Terme
2 Centro di Vulnologia, Istituti Clinici Zucchi, Monza
3 Clinica di Chirurgia Plastica e Ricostruttiva, Università di Ancona
4 Dipartimento di Istologia, Microbiologia e Biotecnologie Mediche, Università di Padova

The healing of chronic skin lesions still poses major problems for health services in developed countries. Numerous advances have been made in understanding the physiology of these, often recalcitrant, lesions, with the consequent development of a selection of new, advanced treatments for the specialist to choose from. In particular, tissue engineering technology has led to the development of viable skin substitutes that have become a valid option for the treatment of chronic lesions, notably, TISSUEtech Autograft SystemTM (TTAS), constituted by an autologous dermal substitute (Hyalograft® 3D) and an autologous epidermal substitute (Laserskin® Autograft). This tissue engineering system has evolved by developing scaffolds based on HYAFF® (a hyaluronic acid ester), on which autologous cells are seeded. There they proliferate, while remaining metabolically active. The clinical efficacy and safety of the TISSUEtech Autograft system have already been demonstrated by earlier clinical trials. In this paper, we present 3 cases of slow-healing wounds, successfully resolved using the autologous tissue engineering system (TTAS), which we believe to be particularly good examples of the mechanisms underlying the clinical efficacy of the products.

language: Italian


FULL TEXT  REPRINTS

top of page